Premium
Runt‐related transcription factor 2 in human colon carcinoma: A potent prognostic factor associated with estrogen receptor
Author(s) -
Sase Tomohiko,
Suzuki Takashi,
Miura Koh,
Shiiba Kenichi,
Sato Ikuro,
Nakamura Yasuhiro,
Takagi Kiyoshi,
Onodera Yoshiaki,
Miki Yasuhiro,
Watanabe Mika,
Ishida Kazuyuki,
Ohnuma Shinobu,
Sasaki Hiroyuki,
Sato Ryuichiro,
Karasawa Hideaki,
Shibata Chikashi,
Unno Michiaki,
Sasaki Iwao,
Sasano Hironobu
Publication year - 2012
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.27525
Subject(s) - runx2 , carcinoma , cancer research , estrogen receptor , biology , metastasis , estrogen , medicine , pathology , endocrinology , cancer , in vitro , breast cancer , osteoblast , biochemistry
Runt‐related transcription factor 2 (RUNX2) belongs to the RUNX family of heterodimeric transcription factors, and is mainly associated with osteogenesis. Previous in vitro studies demonstrated that RUNX2 increased the cell proliferation of mouse and rat colon carcinoma cells but the status of RUNX2 has remained unknown in human colon carcinoma. Therefore, we examined clinical significance and biological functions of RUNX2 in colon carcinoma. RUNX2 immunoreactivity was examined in 157 colon carcinoma tissues using immunohistochemistry. RUNX2 immunoreactivity was evaluated as percentage of positive carcinoma cells [ i.e ., labeling index (LI)]. We used SW480 and DLD‐1 human colon carcinoma cells, expressing estrogen receptor‐β (ER) in subsequent in vitro studies. RUNX2 immunoreactivity was detected in colon carcinoma cells, and the median value of RUNX2 LI was 67%. RUNX2 LI was significantly associated with Dukes' stage, liver metastasis and ERβ status. In addition, RUNX2 LI was significantly associated with adverse clinical outcome of the colon carcinoma patients, and turned out an independent prognostic factor following multivariate analysis. Results of in vitro studies demonstrated that both SW480 and DLD‐1 cells transfected with small interfering RNA against RUNX2 significantly decreased their cell proliferation, migration and invasive properties. In addition, RUNX2 mRNA level was significantly decreased by ER antagonist in these two cells. These findings all suggest that RUNX2 is a potent prognostic factor in human colon carcinoma patients through the promotion of cell proliferation and invasion properties, and is at least partly upregulated by estrogen signals through ERβ of carcinoma cells.